{"id":"otx-tki-axitinib-implant","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypertension"},{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1289926","moleculeType":"Small molecule","molecularWeight":"386.48"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these receptors, OTX-TKI reduces angiogenesis and tumor growth. This mechanism is particularly effective in treating cancers that are dependent on vascular endothelial growth factor for growth and survival.","oneSentence":"OTX-TKI (axitinib implant) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:46.846Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07235085","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy","status":"RECRUITING","sponsor":"Ocular Therapeutix, Inc.","startDate":"2025-11-17","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":930},{"nctId":"NCT06495918","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ocular Therapeutix, Inc.","startDate":"2024-11-27","conditions":"Neovascular Age-related Macular Degeneration","enrollment":825},{"nctId":"NCT06223958","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ocular Therapeutix, Inc.","startDate":"2024-01-29","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":344},{"nctId":"NCT04989699","phase":"PHASE1","title":"Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2021-07-28","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":21},{"nctId":"NCT05695417","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Ocular Therapeutix, Inc.","startDate":"2023-01-15","conditions":"Non-proliferative Diabetic Retinopathy","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OTX-TKI (axitinib implant)","genericName":"OTX-TKI (axitinib implant)","companyName":"Ocular Therapeutix, Inc.","companyId":"ocular-therapeutix-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OTX-TKI (axitinib implant) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors. Used for Metastatic renal cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}